Reevaluation of the South Asian MYBPC3 Δ25bp Intronic Deletion in Hypertrophic Cardiomyopathy
Open Access
- 1 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 13 (3) , 101-109
Abstract
Background: The common intronic deletion, MYBPC3 Δ25 , detected in 4% to 8% of South Asian populations, is reported to be associated with cardiomyopathy, with ≈7-fold increased risk of disease in variant carriers. Here, we examine the contribution of MYBPC3 Δ25 to hypertrophic cardiomyopathy (HCM) in a large patient cohort. Methods: Sequence data from 2 HCM cohorts (n=5393) was analyzed to determine MYBPC3 Δ25 frequency and co-occurrence of pathogenic variants in HCM genes. Case-control and haplotype analyses were performed to compare variant frequencies and assess disease association. Analyses were also undertaken to investigate the pathogenicity of a candidate variant MYBPC3 c.1224-52G>A. Results: Our data suggest that the risk of HCM, previously attributed to MYBPC3 Δ25 , can be explained by enrichment of a derived haplotype, MYBPC3 Δ25/ −52 , whereby a small subset of individuals bear both MYBPC3 Δ25 and a rare pathogenic variant, MYBPC3 c.1224-52G>A. The intronic MYBPC3 c.1224-52G>A variant, which is not routinely evaluated by gene panel or exome sequencing, was detected in ≈1% of our HCM cohort. Conclusions: The MYBPC3 c.1224-52G>A variant explains the disease risk previously associated with MYBPC3 Δ25 in the South Asian population and is one of the most frequent pathogenic variants in HCM in all populations; genotyping services should ensure coverage of this deep intronic mutation. Individuals carrying MYBPC3 Δ25 alone are not at increased risk of HCM, and this variant should not be tested in isolation; this is important for the large majority of the 100 million individuals of South Asian ancestry who carry MYBPC3 Δ25 and would previously have been declared at increased risk of HCM.Keywords
This publication has 16 references indexed in Scilit:
- Advances in the Genetic Basis and Pathogenesis of Sarcomere CardiomyopathiesAnnual Review of Genomics and Human Genetics, 2019
- Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samplesGenetics in Medicine, 2017
- Role of common sarcomeric gene polymorphisms in genetic susceptibility to left ventricular dysfunctionJournal of Genetics, 2016
- Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivityGenetics in Medicine, 2015
- MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutationPflügers Archiv - European Journal of Physiology, 2013
- A low prevalence of MYH7/MYBPC3 mutations among Familial Hypertrophic Cardiomyopathy patients in IndiaMolecular and Cellular Biochemistry, 2011
- A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South AsiaNature Genetics, 2009
- Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and α-Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin FilamentsCirculation Research, 2007
- Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse α-cardiac myosin in the laser trap assayAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the NetherlandsEuropean Heart Journal, 2003